Abstract Glutamate acting on AMPA-type ionotropic glutamate receptor (AMPAR) mediates the majority of fast excitatory synaptic transmission in the mammalian central nervous system. Dynamic regulation of AMPAR by post-translational modifications is one of the key elements that allow the nervous system to adapt to environment stimulations. S-palmitoylation, an important lipid modification by post-translational addition of a long-chain fatty acid to a cysteine residue, regulates AMPA receptor trafficking, which dynamically affects multiple fundamental brain functions, such as learning and memory. In vivo, S-palmitoylation is controlled by palmitoyl acyl transferases and palmitoyl thioesterases. In this review, we highlight advances in the mechanisms for dynamic AMPA receptors palmitoylation, Abbreviations: ABE, acyl-biotinyl exchange; ABP, AMPA receptor binding protein; AD, Alzheimer's disease; AKAP79/150, A-kinase anchoring protein 79/150; AMPAR, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor; APT1, acyl-protein thioesterase-1; APT2, acyl-protein thioesterase-2; CP-AMPARs, Ca 2þ -permeable AMPARs; DHHC, aspartate-histidine-histidine-cysteine; FMRP, fragile X mental retardation protein; FXS, Fragile X syndrome; GAP-43, growth associated protein-43; GRIP, glutamate receptor interacting protein; LTD, long-term depression; LTP, long-term potentiation; 17-ODYA, 17-octadecynoic acid; PATs, palmitoyl acyl transferases; PDZ, postsynaptic density-95/discs large/zona occludens-1; PICK1, protein interacting with C-kinase 1; PKA, protein kinase A; PKC, protein kinase C; PPT1, palmitoyl-protein thioesterase-1; PSD-95, postsynaptic density-95; Ras, rat sarcoma; SNAP-23, soluble N-ethylmaleimide-sensitive fusion protein-attachment protein receptor protein-23
and discuss how palmitoylation affects AMPA receptors function at synapses in recent years. Pharmacological regulation of S-palmitoylation may serve as a novel therapeutic strategy for neurobiological diseases.
Introduction
Glutamate is the primary excitatory neurotransmitter in the mammalian central nervous system. As an important ionotropic glutamate receptor, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor (AMPAR) mediates the fast excitatory synaptic transmission in the mammalian brain 1 . The plenty of AMPARs at synapses plays a pivotal role in determining synaptic efficacy. An abundance of convincing evidence has shown that AMPAR is a crucial factor in normal cellular and synaptic activities and in the pathogenesis of multifarious neuropsychiatric and neurodegenerative diseases 1 . Only 30%-50% of AMPARs are expressed on the surface of neurons and a significant proportion of intracellular receptors are located in dendrites. Dynamics of AMPARs at synapse provide a compelling mechanism for understanding the cellular basis of neuropsychiatric and neurodegenerative diseases. S-palmitoylation, a principal type of lipid modifications, controls functions of various neuronal proteins by affecting their surface trafficking, including AMPARs. This process is mainly mediated by post-translational addition of a long-chain fatty acid to a cysteine residue of AMPARs or its regulators via a thioester linkage. Considering the critical role of AMPARs in the central nerve system function and neurobiological diseases, regulation of their dynamical trafficking by Spalmitoylation also serves as a predominant determinant of multiple fundamental brain functions and pathological process. Pharmacological regulation of S-palmitoylation may emerge as a potential therapeutic strategy for neurobiological diseases in the future.
What is palmitoylation?
Protein lipid modification, one important post-translational modification, commonly includes isoprenylation 2 , myristoylation 3 , glycophosphatidyl inositol and palmitoylation [4] [5] [6] . Among them, palmitoylation is a sort of major lipid modifications of proteins. It is defined as the covalent attachment of saturated 16-carbon palmitic acid to specific cysteine and less frequently to serine and threonine residues of proteins 4, 7 . From aspect of chemical biology, palmitoylation increases the hydrophobicity of targeted proteins and facilitates their membrane association (Fig. 1A) . Depending on the site of palmitoylation, it can be divided into Npalmitoylation and S-palmitoylation (Fig. 1B) . N-palmitoylation, through the formation of a stable N-amide bond, was discovered via the analysis of the secreted morphogen Sonic Hedgehog 8 . Furthermore, the N-palmitoylation of sonic hedgehog proteins is stable and irreversible 9 . On the contrary, S-palmitoylation, through the formation of a labile thioester bond, is a distinctive, reversible lipid modification 4 , and potentially regulates the function of proteins via cycles of palmitoylation and depalmitoylation catalyzed by protein palmitoyltransferases and protein thioesterases respectively (Fig. 1C) . This review focuses on the effect of Spalmitoylation on AMPARs function.
Palmitoylation-related enzymes
As a class of aspartate-histidine-histidine-cysteine (DHHC) proteins (also known as ZDHHC proteins) [10] [11] [12] [13] [14] [15] , palmitoyl acyl transferases (PATs) 14, 15 containing a genetically conserved DHHC cysteine-rich domain (the catalytic center of the enzyme) 16 catalyze palmitoylation of multiple targets in vivo. PATs were first discovered in Saccharomyces cerevisiae 12, 13 and subsequently in various of mammalian cells 11, [17] [18] [19] [20] [21] [22] [23] . So far, 23 mammalian DHHC proteins and their targets have been discovered 11, 24 ( Fig. 1D ). For example, in the past several decades, several studies have demonstrated that AMPARs subunits-GluA1 and GluA2 can be palmitoylated by DHHC3, which regulates AMPARs surface expression 21 . PSD95, as a scaffolding protein, was also palmitoylated by DHHC 2, 15, 3, and 7 25 . Recent study shows that DHHC8 can palmitoylate protein interacting with C-kinase 1 (PICK1), as a PDZ domain-containing protein, which is required for cerebellar long-term depression (LTD) in mouse 26 . Palmitoylation of both AMPAR subunits and synaptic scaffolding proteins affects synaptic function assembly 25, 26 .
Depalmitoylation-related enzymes
Depalmitoylation is catalyzed by palmitoyl protein thioesterases, such as palmitoyl-protein thioesterase-1 (PPT1), acyl-protein thioesterase-1 (APT1) and acyl-protein thioesterase-2 (APT2). Palmitoyl protein thioesterases remove thioester-linked saturated 16-carbon palmitic acid from modified cysteine residues in proteins or peptides during lysosomal degradation. APT1 is a unique thioesterase which is engaged in depalmitoylation of cytoplasmic proteins, such as Ras (rat sarcoma), G α subunits, endothelial nitric oxide synthase and SNAP-23 (soluble N-ethylmaleimide-sensitive fusion proteinattachment protein receptor protein-23) [27] [28] [29] [30] . APT2 catalyzes the depalmitoylation of peripheral membrane-associated GAP-43 (growth associated protein-43) 28 . Besides as a thioesterase, PPT1 is a lysosomal enzyme associated with the degradation of palmitoylated proteins 28, 31 , and the deficit of PPT1 causes neuronal ceroid lipofuscinosis of infants 30 .
Direct regulation of AMPARs trafficking by selfpalmitoylation
AMPARs are heterotetrameric and ionotropic glutamate receptors, consisted of 4 subunits: GluA1-4 32 . In mammals, AMPARs are highly conserved. GluA4-containing forms predominantly appear in early postnatal development, while heteromers of GluA1-GluA2 and GluA2-GluA3 mainly exist in the mature mammalian hippocampus 33, 34 .
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AMPARs surface delivery is a crucial procedure in the synaptic transmission and synaptic plasticity. Palmitoylation of AMPARs is a subunit-specific process which affects its trafficking 35 . Thus, palmitoylation of AMPARs plays a crucial role in the regulation of AMPARs function 21, 35, 36 . The dynamic regulation of palmitoylation and depalmitoylation provides a pivotal mechanism for synaptic plasticity.
Two sites of AMPARs can be directly palmitoylated. One site is the cysteine-610 in the second transmembrane domain of GluA1 and GluA2. The other is different between GluA1 and GluA2. GluA1 ( Fig. 2A) and GluA2 (Fig. 2B ) are palmitoylated at cysteine-811 and cysteine-836 respectively in the juxtatransmembrane region of the C-terminal cytoplasmic tail 21 . In GluA1, palmitoylation of cysteine-811 indirectly affects AMPARs trafficking to the cell surface through decreasing interaction with the protein band 4.1N 21 , which is relative to stabilize surface expression of GluA1 11 ( Fig. 2A) . Notably, neuronal activity highly regulates palmitoylation of AMPARs. Depalmitoylation of AMPARs is rapidly induced by the stimulation of glutamate. But the level of total receptors in neuronal cultures are not altered 21, 35 . DHHC3, as a PAT, catalyzes palmitoylation of the transmembrane domain site of AMPARs. Thus, it may negatively regulate AMPARs trafficking, and affect expression of AMPARs on the plasma membrane 21 . However, its precise role in synaptic plasticity remains yet largely unknown.
Indirect regulation of AMPARs trafficking via palmitoylation and AMPAR-interacting proteins
Many AMPAR-interacting proteins that control surface insertion of AMPARs have been identified, such as postsynaptic density-95 (PSD-95), glutamate receptor interacting protein (GRIP)/AMPA receptor binding protein (ABP), PICK1, 4.1N and the A-kinase anchoring protein 79/150 (AKAP79/150). Palmitoylation of these proteins facilitates their membrane association, stabilizes their postsynaptic density and increases their interactions with intracellular receptors 15 . Thus, palmitoylation of AMPAR-associated proteins always produce a contrary effect in contrast to the palmitoylation of AMPARs.
The palmitoylation of PSD-95 and AMPARs trafficking
PSD-95 is a major scaffolding protein in postsynaptic density, and its palmitoylation is pivotal for AMPARs trafficking 37 . The surface expression of AMPARs is dynamically increased by palmitoylation of PSD-95 25 . The palmitoylated sites of PSD-95 are cysteines-3 and -5 at the N-terminus of the protein. The mutation of the palmitoylated sites on PSD-95 blocks its palmitoylation, and notably decreases surface expression of AMPARs 37 . The N-terminal palmitoylation is essential for stabilization of PSD-95 within the postsynaptic density 39 . And DHHC 2, 3, 5, 7, 8, and 15, a series of DHHC-PAT family members, catalyze PSD-95 palmitoylation 15 . Among these DHHCs, DHHC3 and DHHC2 are both essential in the process of postsynaptic accumulation of PSD-95, but only DHHC2 is implicated in the palmitoylation of PSD-95 in response to the decreasing synaptic activity 40 . The decreasing neuronal activity initiates a rapid mobilization of dendritic DHHC2 close to the postsynaptic membranes, therefore mediating robust palmitoylation and improving synaptic accumulation of PSD-95. Finally, it contributes to the increasing surface expression of AMPARs after neuronal stimulation 40 . Regulation of PSD-95 palmitoylation may serve as a novel target for controlling AMPARs surface delivery. Although the lack of selective pharmacological antagonist, we may use the specific peptide to inhibit palmitoylation of PSD-95 by intervening interaction between DHHCs and PSD-95 in the future.
The palmitoylation of GRIP/ABP and AMPARs trafficking
GRIP also called ABP, with a multi-PDZ domain scaffold, links and stabilizes AMPAR GluA2/3 subunits at synapses. Palmitoylated N-terminal splice variant expression specifically induces multiple changes relative to non-palmitoylated form, contributing to increase of synaptic transmission and AMPARs surface trafficking, as well as development of presynapse and postsynapse 41 . GRIP1 targets to the endosome, and controls the dynamic recycling of internalized AMPARs back to the plasma membrane 42 . GRIP1b mediates NMDA-induced AMPARs internalization, and GRIP1a inhibits this process 43 . Furthermore, GRIP1b, targeting to trafficking endosomes, palmitoylated by DHHC5/8, mediates activity-dependent AMPARs trafficking 44 .
The palmitoylation of PICK1 and AMPARs trafficking
PICK1, a key candidate as a bidirectional regulator of synaptic AMPARs trafficking, mediates the trafficking of GluR2/3 and participate in many physiological and pathological processes. As a postsynaptic density-95/discs large/zona occludens-1 (PDZ) domain protein, PICK1 binds directly with the C termini of the GluA2 and GluA3 subunits of AMPARs 45, 46 . PICK1 plays an inverse role in regulating the membrane expression of GluA2-containing and GluA2-lacking Ca 2þ -permeable AMPARs (CPAMPARs). The membrane expression of GluA2 was decreased in PICK1 over-expressed neurons, while the surface expression of CP-AMPARs was increased 47 . On the contrary, knockout of PICK1 reduced surface expression of CP-AMPARs in cultured neurons, but the levels of surface GluA2/3 were elevated 48, 49 . Palmitoylation on cysteine-414 50 juxta-C terminus of PICK1 by DHHC8 26 contributes to the internalization of postsynaptic GluA2-containing AMPARs 51 , which is essential for cerebellar LTD. and calcineurin to the PSD to regulate its phosphorylation, which controls trafficking process of AMPARs [55] [56] [57] [58] [59] [60] [61] . The neuronal activity regulates palmitoylation of AKAP79/150, and mediates its targeting to postsynaptic membrane lipid rafts and dendritic endosomes. Crucially, spine enlargement, endosome recycling, and AMPARs trafficking pathways associated with long-term potentiation (LTP) are regulated by the palmitoylation of AKAP79/150 62 .
4.1N and palmitoylation of AMPARs

AMPARs trafficking in disease
Disorder of the synaptic AMPARs trafficking contributes to cognitive dysfunction in Alzheimer's disease (AD). The expression level of AMPAR subunits, such as GluA1, GluA2 and GluA2/3, was decreased in CA1 of hippocampus, the subiculum and entorhinal cortex of patients with AD 63, 64 . Fragile X syndrome (FXS), caused by the loss of fragile X mental retardation protein (FMRP) 65 , also associates with dysregulation of AMPARs trafficking. The translation level of GluA1 and GluA2 subunits was significantly increased 65 , but the surface expression level of GluA1 is reduced in the amygdala of fragile X mental retardation 1 (Fmr1) knock-out mice 66 . However, there are few reports on palmitoylation regulates AMPARs trafficking in neurobiological diseases.
Conclusions and perspectives
We have seen considerable steps forward in our understanding of the extent and roles of palmitoylation of AMPARs and their regulators in past several decades. The development of two complemental methods have been used in the global palmitoyl proteomic analysis. The acyl-biotinyl exchange (ABE) method [67] [68] [69] can be applied to analyze palmitoylated proteins from any cell-free protein extract. In contrast to the ABE method, metabolic labeling with the 17-octadecynoic acid (17-ODYA, as the palmitic acid analog) 70, 71 can identify dynamically palmitoylated proteins in vivo.
The large DHHC family plays essential roles in a range of physiological functions, and several DHHC genes are closely associated with diseases, such as cancers 72 , schizophrenia 73, 74 , mental retardation 75, 76 , and Huntington's disease 77 . However, how the DHHCs dynamically regulate palmitoylation of targeted proteins in several diseases including neuropsychiatric disorder yet remains elusive.
Palmitoylation of postsynaptic proteins, such as PSD-95 and GRIP1, may up-regulate the membrane expression of AMPARs, and enhance the synaptic function 15 . Consequently, palmitoylation-dependent regulation of AMPARs trafficking inevitably plays pivotal roles in physiological activities of neurons and synapses, and in the pathogenesis of multiple neuropsychiatric and neurodegenerative diseases, such as cocaine addiction 78 . Both the pharmacological antagonist of PATs 2-bromopalmitate 44 and shRNA knockdown or rescue approaches 62 are widely used to explore the roles of specific palmitoylation events. Recently, 2-bromopalmitate analogs (1,2-bromohexadec-15-ynoic acid and 2-bromooctadec-17-ynoic acid), serve as novel and chemical tools to probe PATs in cell signaling and diseases 79 . But it is a pity that the 2-bromopalmitate analogs are not selective to pharmacologically antagonize one of PATs. Considering the key role of palmitoylation in the regulation of AMPARs function, these PATs inhibitors may serve as medicinal approaches to rescue neuropsychiatric and neurodegenerative diseases in the future.
Regardless of these progresses in research on palmitoylation of AMPARs, there are many mechanisms on dynamical regulation of between palmitoylation and depalmitoylation remain elusive. Therefore what primary challenges lie ahead?
First and foremost, a selective pharmacological antagonist for PATs is lacking. 2-Bromopalmitate, pervasively used in palmitoylation of studies, can block all of PATs. It causes a serious trouble for our research on a specific type of PAT. Consequently, it is high time that we found specific and selective pharmacological antagonists for PATs which is helpful for the studies on palmitoylation of AMPARs, even for all of researches about palmitoylation.
Besides, until now, most studies focused on the physiological role of palmitoylation, but little reports about the role of palmitoylation in pathogenesis of neuropsychiatric disorders, including major depressive disorder, drug addiction and posttraumatic stress disorder, have been revealed. Surface delivery of AMPARs plays a principal role in pathogenesis of neuropsychiatric disorders; interestingly, palmitoylation regulates AMPARs trafficking. Therefore, we should pay more attention to the role of palmitoylation in the neuropsychiatric diseases. A clarification for the relationship between palmitoylation in the blood and neuropsychiatric disorders will ultimately translate AMPARs modifications from laboratory to bedside. Furthermore, palmitoylating/depalmitoylating enzymes associated with AMPAR trafficking might become potential therapeutic targets of neuropsychiatric disorders in the future.
